reservoir 1 is 10-200 µg/d, preferably 10-100 µg/d, for a period of at least three months.

15. The intrauterine delivery system according to claim 13, characterized in that the release rate of 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one from reservoir 2 is 1-20 µg/d, preferably 1-10 µg/d for a period of at least three years.

16. The intrauterine delivery system according to any one of claims 1-12, characterized in that the progestogenic compound in both reservoirs is levonorgestrel.

17. The intrauterine delivery system according to claim 16, characterized in that the release rate of Levonorgestrel from reservoir 1 is 20-100 µg/d, preferably 20-50 µg/d, for a period of at least three months.

18. The intrauterine delivery system according to claim 16, characterized in that the release rate of Levonorgestrel from reservoir 2 is 5-30 µg/d, preferably 5-20 µg/d, for a period of at least three years.

~~19. An improved method of contraception and for preventing or suppressing initial bleeding and spotting associated with the use of intrauterine delivery systems, wherein an intrauterine delivery system is used for the controlled release of progestogen or a drug having progestogenic activity over a prolonged period of time and at a level required for contraception and wherein said intrauterine delivery system comprises a body construction and two reservoirs comprising a core and a membrane encasing the core, the core and membrane consisting of a same or different polymer composition, characterized in that the release rates and times of release from said reservoirs are different.~~